Picard Medical, the medical device company listed on the London Stock Exchange, has announced that its board has approved a 1-for-50 reverse stock split. The decision, confirmed on 22 July 2026, is designed to consolidate the company's share capital and lift its stock price above the minimum required for continued listing on the main market.
Under the reverse split, every 50 existing ordinary shares will be converted into one new share. While the total value of each shareholder's stake remains unchanged in theory, the move reflects the company's struggle to maintain investor confidence. Picard Medical's shares had been trading at penny-stock levels for several months, raising concerns about its eligibility to remain on the exchange.
The FTSE 250 index, where Picard was previously listed, has seen a rotation away from smaller-cap healthcare stocks this year, with the sector down roughly 4% since January. Analysts at Shore Capital noted that reverse splits are often viewed as a sign of distress, though they can provide a temporary reprieve from delisting. 'It buys time, but it does not address the underlying operational challenges,' one analyst said.
For UK pension holders and retail investors, the split does not change the fundamental value of their holdings, but it may affect liquidity. Shares that were previously affordable for small traders could become more expensive per unit, potentially narrowing the pool of buyers. The company has not provided a timeline for when the split will take effect, pending regulatory approvals.
Picard Medical's financial results for the first half of 2026 have not yet been released, but the company has faced headwinds from rising manufacturing costs and supply chain delays. The reverse split is the latest in a series of measures aimed at stabilising the business, which also includes a review of non-core assets.